Inflammation News and Research

RSS

Natural options against weight gain, sugar cravings, and insulin resistance

The holidays have come and gone, but many of us may still be battling intense sweet cravings leftover from the season's festivities. Excessive sugar cravings can be a sign that your blood glucose levels are out of balance which, if left unchecked, can lead to insulin resistance and Metabolic Syndrome, also known as "Pre-Diabetes."

11 Jan 2012

Intestinal worm infections may not be bad

Intestinal worm infections may not be all bad, according to a new study by William C. Gause, PhD, and colleagues at UMDNJ- New Jersey Medical School. The researchers have found cytokines that help oust intestinal worm infections in mice also soothe associated lung injury and inflammation.

11 Jan 2012

Damon Runyon Cancer Research Foundation names 18 new Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

11 Jan 2012

New possibilities for effective treatment of psoriasis

Researchers at Link-ping University in Sweden are now launching a plan to effectively treat psoriasis.

11 Jan 2012

Study examines impact of maternal obesity on inflammatory responses

A number of different immunological mechanisms ensure the successful establishment and maintenance of pregnancy. Imbalance in these mechanisms is associated with adverse pregnancy outcomes.

11 Jan 2012

Baro-Therapies introduces portable barometric therapy device for pain, inflammation

Baro-Therapies, Inc. has announced the national launch of The Rejuvenator, a portable barometric therapy device that provides drug-free relief from inflammatory pain and neurological conditions using elevated barometric pressure.

11 Jan 2012

UCLA researchers identify chemical changes in brains of patients with early-onset Alzheimer's

With a lack of effective treatments for Alzheimer's, most of us would think long and hard about whether we wanted to know years in advance if we were genetically predisposed to develop the disease. For researchers, however, such knowledge is a window into Alzheimer's disease's evolution.

11 Jan 2012

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.

9 Jan 2012

New Zealand life science and health IT companies to showcase their products in San Francisco

New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand life sciences companies who have reached key stages in their development are joining the throngs of international therapeutics, medical device and health IT companies in San Francisco, January 9 - 12 to showcase their products and capabilities to potential corporate partners and investors.

7 Jan 2012

Statin use may influence susceptibility to ILD in smokers

Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

6 Jan 2012

Study shows how Epstein-Barr virus triggers MS

A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

6 Jan 2012

Celtaxsys announces acquisition of CTX-4430 from Estrellita

Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

6 Jan 2012

New laboratory approach could aid brain recovery

In humans, active periods of the debilitating disease Multiple Sclerosis (MS) can last for mere minutes or extend to weeks at a time. They're caused by lesions in the brain that develop, partly heal, and then recur. Research into a cure has been difficult, because to date scientists have not been able to replicate these brain recurring symptoms in laboratory mice. That's frustrating because these lab animals, known as animal "models," are the primary tool for research into the mechanisms and potential treatments for MS.

6 Jan 2012

Repeated episodes of depression contribute to inflammation

An important ongoing debate in the field of psychiatry is whether inflammation in the body is a consequence of or contributor to major depression. A new study in Biological Psychiatry has attempted to resolve the issue.

5 Jan 2012

Vitamin D may stop conferring cardiovascular benefits: Study

New research by Johns Hopkins scientists suggests that vitamin D, long known to be important for bone health and in recent years also for heart protection, may stop conferring cardiovascular benefits and could actually cause harm as levels in the blood rise above the low end of what is considered normal.

5 Jan 2012

Free public lecture to look at role of stents in treating coronary artery diseases

State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.

5 Jan 2012

Rilonacept appears safe and well-tolerated in patients with gout

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.

5 Jan 2012

Study finds increase in incidence and prevalence of IBD

The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time and in different regions around the world, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

5 Jan 2012

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011.

4 Jan 2012

Researchers discover culprit that leads from heart failure to diabetes

Either heart failure or diabetes alone is bad enough, but oftentimes the two conditions seem to go together. Now, researchers reporting in the January Cell Metabolism appear to have found the culprit that leads from heart failure to diabetes and perhaps a novel way to break that metabolic vicious cycle.

4 Jan 2012